Cardiovascular was the largest of Boston Scientific Corp’s 2 reported lines in fiscal 2025, at $16.30B — 63% of $25.73B.
| Segment | FY 2008 | FY 2009 | FY 2010 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bsx Reportable Segments | — | — | — | — | ||||||||
| Cardiovascular | $8.64B | $9.62B | $12.31B | $16.30B | ||||||||
| Medsurg | $6.62B | $7.23B | $8.11B | $9.43B | ||||||||
| Rhythm & Neuro | — | — | — | — | ||||||||
| Cardiac Rhythm Management | — | — | — | — | ||||||||
| Endoscopy | — | — | — | — | ||||||||
| Urology Women'S/Health | — | — | — | — | ||||||||
| Neurovascular | — | — | — | — | ||||||||
| Neuromodulation | — | — | — | — | ||||||||
| Electrophysiology | — | — | — | — | ||||||||
| Total | $15.26B | $16.85B | $20.42B | $25.73B |
In fiscal 2025, which ended December 31, 2025, the 2 segments Boston Scientific Corp reported in this breakdown added up to $25.73B. That was up 26.0% from $20.42B in fiscal 2024. Cardiovascular was the largest segment, at $16.30B or 63.3% of the total, followed by Medsurg ($9.43B, 36.7%).
Compared with fiscal 2024, Cardiovascular grew the fastest, rising 32.4% to $16.30B. Over fiscal 2022 to 2025, revenue across these segments went from $15.26B to $25.73B, a compound annual growth rate of 19.0%. Cardiovascular's share of the total rose from 56.6% to 63.3% over the same years.
The table also keeps 8 segments that Boston Scientific Corp no longer reports, so earlier years can still be read on their original basis; use "Show 8 discontinued" beneath the table to see them. This breakdown covers 12 fiscal years between 2008 and 2025, as reported in Boston Scientific Corp's annual filings.
Boston Scientific Corp (BSX) breaks its revenue down by segment. In fiscal 2025, its largest segment was Cardiovascular, with $16.30B or 63.3% of the total, followed by Medsurg at $9.43B (36.7%).
Cardiovascular was Boston Scientific Corp's largest segment in fiscal 2025, with $16.30B in revenue, 63.3% of the $25.73B reported across its 2 segments.
Of the Boston Scientific Corp segments reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Cardiovascular grew the fastest, rising 32.4% from $12.31B to $16.30B.
Every figure is taken from Boston Scientific Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2008 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.